|Examples of findings in Beckwith–Wiedemann syndrome|
Beckwith–Wiedemann syndrome (/ˈbɛkˌwɪθ ˈviːdə.mən/; abbreviated BWS) is an overgrowth disorder usually present at birth, characterized by an increased risk of childhood cancer and certain congenital features. A minority (<15%) of cases of BWS are familial, meaning that a close relative may also have BWS, and parents of an affected child may be at increased risk of having other children with BWS. While children with BWS are at increased risk of childhood cancer, most children with BWS do not develop cancer and the vast majority of children who do develop cancer can be treated successfully.
No consensus clinical diagnostic criteria for Beckwith–Wiedemann syndrome (BWS) exist. Beckwith–Wiedemann syndrome (BWS) should be suspected in individuals who have one or more of the following major and/or minor findings.
Major findings associated with BWS
- Macrosomia (traditionally defined as weight and length/height >97th centile)
- Hemihyperplasia (asymmetric overgrowth of one or more regions of the body)
- Omphalocele (also called exomphalos) or umbilical hernia
- Embryonal tumor (e.g., Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma) in childhood
- Visceromegaly involving one or more intra-abdominal organs including liver, spleen, kidneys, adrenal glands, and/or pancreas
- Cytomegaly of the fetal adrenal cortex (pathognomonic)
- Renal abnormalities including structural abnormalities, nephromegaly, nephrocalcinosis, and/or later development of medullary sponge kidney
- Anterior linear ear lobe creases and/or posterior helical ear pits
- Placental mesenchymal dysplasia
- Cleft palate (rare in BWS)
- Cardiomyopathy (rare in BWS)
- Positive family history (≥1 family members with a clinical diagnosis of BWS or a history or features suggestive of BWS)
Minor findings associated with BWS
- Pregnancy-related findings including polyhydramnios and prematurity in fetuses with the condition.
- Neonatal hypoglycemia
- Vascular lesions including nevus simplex (typically appearing on the forehead, glabella, and/or back of the neck) or hemangiomas (cutaneous or extracutaneous)
- Characteristic facies including midface retrusion and infraorbital creases
- Structural cardiac anomalies or cardiomegaly
- Diastasis recti
- Advanced bone age (common in overgrowth/endocrine disorders)
The diagnosis of BWS is established in a proband with either of the following:
- Three major or two major plus at least one minor criteria (BWS should be considered a clinical spectrum, with some affected individuals having only one or two suggestive clinical findings. Therefore, the generally accepted clinical criteria proposed here should not be viewed as absolute but rather as guidelines. In other words, they cannot be used to rule out a diagnosis of BWS and cannot substitute for clinical judgment.)
- An epigenetic or genomic alteration leading to abnormal methylation at 11p15.5 or a heterozygous BWS-causing pathogenic variant in CDKN1C in the presence of one or more clinical findings
Most children with BWS do not have all of these features. In addition, some children with BWS have other findings including: nevus flammeus, prominent occiput, midface hypoplasia, hemihypertrophy, genitourinary anomalies (enlarged kidneys), cardiac anomalies, musculoskeletal abnormalities, and hearing loss. Also, some premature newborns with BWS do not have macroglossia until closer to their anticipated delivery date.
Given the variation among individuals with BWS and the lack of a simple diagnostic test, identifying BWS can be difficult. In an attempt to standardize the classification of BWS, DeBaun et al. have defined a child as having BWS if the child has been diagnosed by a physician as having BWS and if the child has at least two of the five common features associated with BWS (macroglossia, macrosomia, midline abdominal wall defects, ear creases, neonatal hypoglycemia). Another definition presented by Elliot et al. includes the presence of either three major features (anterior abdominal wall defect, macroglossia, or prepostnatal overgrowth) or two major plus three minor findings (ear creases, nevus flammeus, neonatal hypoglycemia, nephromegaly, or hemihyperplasia).
In general, children with BWS do very well and grow up to become adults of normal size and intelligence, usually without the syndromic features of their childhood.
Most children (>80%) with BWS do not develop cancer; however, children with BWS are much more likely (~600 times more) than other children to develop certain childhood cancers, particularly Wilms' tumor (nephroblastoma), pancreatoblastoma, and hepatoblastoma. Individuals with BWS appear to only be at increased risk for cancer during childhood (especially before age four) and do not have an increased risk of developing cancer in adulthood. If 100 children with BWS were followed from birth until age ten, about 10 cases of cancer would be expected in the group before age four, and about 1 case of cancer in the group would be expected between age four and ten. In addition to Wilms tumor and hepatoblastoma, children with BWS have been shown in individual case reports to develop ganglioneuroma, adrenocortical carcinoma, acute lymphoid leukemia, liver sarcoma, thyroid carcinoma, melanoma, rhabdomyosarcoma, and mesoblastic nephroma.
Wilms tumor, hepatoblastoma, and mesoblastic nephroma can usually be cured if diagnosed early. Early diagnosis allows physicians to treat the cancer when it is at an early stage. In addition, there is less toxic treatment. Given the importance of early diagnosis, all children with BWS should receive cancer screening.
An abdominal ultrasound every 3 months until at least eight years of age is recommended and a blood test to measure alpha-fetoprotein (AFP) every 6 weeks until at least four years of age. Families and physicians should determine screening schedules for specific patients, especially the age at which to discontinue screening, based upon their own evaluation of the risk-benefit ratio.
Most (>85%) cases of BWS are sporadic, meaning that, typically, no one else in that family has BWS, and parents of an affected child are not at increased risk of having other children with BWS. However, some (<15%) cases of BWS are familial, meaning that a close relative may also have BWS, and parents of an affected child may be at increased risk of having other children with BWS. BWS has been shown to specifically involve mutations in a defined region on the short arm of chromosome 11 referred to as 11p15.5, that leads to overactivity of the IGF-2 gene (growth factor) and/or no active copy of CDKN1C (inhibitor of cell proliferation gene).
BWS can be caused by a range of different genetic defects. Over five distinct errors involving 11p15.5 have been identified in different BWS patients. Some patients have maternal chromosomal rearrangements of 11p15.5. Other patients have paternal uniparental disomy (UPD) of chromosome 11, meaning that the maternal copy of this chromosome is replaced with an extra paternal copy. Many other patients have abnormal DNA methylation in different areas of 11p15.5, meaning that normal epigenetic marks that regulate imprinted genes in this region are altered. A few other patients have a single gene copy located within 11p15, instead of two copies.
The absence of a mutation in a child with clinical findings suggestive of BWS should not preclude a diagnosis of BWS. Even after extensive molecular testing, the specific defect causing BWS in an affected individual may remain unknown. BWS remains a clinical, rather than genetic, diagnosis, since physicians cannot identify and test for all the genetic causes of BWS. The clinical definition used for BWS is limited, because no standard diagnostic criteria exist that have been independently verified with patients who have either genetic or epigenetic mutations. When molecular analyses were completed in 10 children who met a research criterion for BWS, only 7 of the 10 children had genetic or epigenetic mutations.
Given that the genetics of BWS are complex, a child with BWS should be under the medical care of a geneticist or an expert in the management of BWS.
Genes involved are IGF-2, CDKN1C, H19, and KCNQ1OT1.
Association with CDKN1C
CDKN1C is a protein-coding gene that encodes a cyclin-dependent kinase inhibitor that acts as a negative regulator of cell proliferation, effectively making CDKN1C a tumor suppressor gene. CDKN1C also works during fetal development, preventing the fetus from becoming too large. It is located on the short arm of the human chromosome 11 in the ICR2 region, along with many other imprinted genes. Since CDKN1C is preferentially maternally expressed, hypomethylation in the ICR2 region of the maternal allele can result in pathologies such as cancer or a defect known as Beckwith-Weidemann Syndrome. Beckwith-Weidemann Syndrome (BWS) may also be brought about by CDKN1C 11p15 epimutations. It may also be a result of deletions of small amounts of DNA that cause chromosomal abnormalities, rendering the gene inactive. This leaves only the paternally expressed IGF2 to promote cell proliferation. The reduction of growth restriction results in the overgrowth of many tissues, leading to the common symptoms of BWS. These symptoms may include macroglossia, organomegaly, periorbital fullness, and hernias. Knockout models for CDKN1C in mice do exist; in fact, many of the affected offspring exhibit fetal and neonatal lethality and have most of the features related to Beckwith-Weidemann Syndrome.
Abdominal wall defects are common in newborns with BWS and may require surgical treatment. These defects can range in severity from omphalocele (most serious) to umbilical hernia and diastasis recti (least serious). An omphalocele is a congenital malformation in which a newborn's intestines, and sometimes other abdominal organs, protrude out of the abdomen through the umbilicus. Newborns with an omphalocele typically require surgery to place the abdominal contents back into the abdomen in order to prevent serious infection or shock. An umbilical hernia is also a defect in which abdominal contents come through weak abdominal wall muscle at the umbilicus. In general, newborns with umbilical hernias do not require treatment because often these hernias spontaneously close by age four. If, after this time, a hernia is still present, surgery may be recommended. Diastasis recti is a separation of the left and right sides of the rectus abdominis muscle that are normally joined. Children with diastasis recti usually require no treatment because the condition resolves as the child grows.
Neonatal hypoglycemia, low blood glucose in the first month of life, occurs in about half of children with BWS. Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days. However, untreated persistent hypoglycemia can lead to permanent brain damage. Hypoglycemia in newborns with BWS should be managed according to standard protocols for treating neonatal hypoglycemia. Usually this hypoglycemia can easily be treated with more frequent feedings or medical doses of glucose. Rarely (<5%) children with BWS will continue to have hypoglycemia after the neonatal period and require more intensive treatment. Such children may require tube feedings, oral hyperglycemic medicines, or a partial pancreatectomy.
Macroglossia, a large tongue, is a very common (>90%) and prominent feature of BWS. Infants with BWS and macroglossia typically cannot fully close their mouth in front of their large tongue, causing it to protrude out. Macroglossia in BWS becomes less noticeable with age and often requires no treatment; but it does cause problems for some children with BWS. In severe cases, macroglossia can cause respiratory, feeding, and speech difficulties. Children with BWS and significant macroglossia should be evaluated by a craniofacial team.
The best time to perform surgery for a large tongue is not known. Some surgeons recommend performing the surgery between 3 and 6 months of age. Surgery for macroglossia involves removing a small part of the tongue so that it fits within the mouth to allow for proper jaw and tooth development.
These children are often managed by a multidisciplinary craniofacial team. These teams include speech and language therapists, craniofacial and paediatric plastic surgeons, and orthodontists who decide the appropriateness and timing of tongue reduction surgery. Some countries have designated centres for the management of macroglossia. For example, in the United Kingdom , children who have macroglossia associated with Beckwith Wiedemann Syndrome are managed in a national specialised service. The service is commissioned as highly specialised service by NHS England and is located at Great Ormond Street Hospital.
Nevus flammeus (port-wine stain) is a flat, red birthmark caused by a capillary (small blood vessel) malformation. Children with BWS often have nevus flammeus on their forehead or the back of their neck. Nevus flammeus is benign and commonly does not require any treatment.
Hemihypertrophy (hemihyperplasia) is an abnormal asymmetry between the left and right sides of the body occurring when one part of the body grows faster than normal. Children with BWS and hemihypertrophy can have an isolated asymmetry of one body part, or they can have a difference affecting the entire one side of the body. Individuals who do not have BWS can also have hemihypertrophy. Isolated hemihypertrophy is associated with a higher risk for cancer. The types of cancer and age of the cancers are similar to children with BWS. As a result, children with hemihypertrophy should follow the general cancer screening protocol for BWS.
Hemihypertrophy can also cause various orthopedic problems, so children with significant limb hemihyperplasia should be evaluated and followed by an orthopedic surgeon.
Hemihyperplasia affecting the face can sometimes cause significant cosmetic concerns that may be addressed by a cranial facial team.
In general, the prognosis is very good. Children with BWS usually do very well and grow up to become the heights expected based on their parents' heights. While they are at increased risk of childhood cancer, most of them do not develop the disease, and the vast majority of the children who do can be treated successfully.
Children with BWS for the most part had no significant delays when compared to their siblings. However, some of them do have speech problems that could be related to macroglossia or hearing loss.
Advances in treating neonatal complications and premature infants in the last twenty years have significantly improved the true infant mortality rate associated with BWS. In a review of pregnancies that resulted in 304 children with BWS, no neonatal deaths were reported. This is compared to a previously reported mortality rate of 20%. The data from the former study was derived from a BWS registry, a database that may be slightly biased towards involving living children; however, death was not an exclusion criterion to join the registry. This suggests that while infants with BWS are likely to have a higher than normal infant mortality risk, it may not be as high as 20%.
Assisted reproductive technology
Assisted reproductive technology (ART) is a general term referring to methods used to achieve pregnancy by artificial or partially artificial means. According to the CDC, in general, ART procedures involve surgically removing eggs from a woman's ovaries, combining them with sperm in the laboratory, and returning them to the woman's body or donating them to another woman. ART has been associated with epigenetic syndromes, specifically BWS and Angelman syndrome. Three groups have shown an increased rate of ART conception in children with BWS. A retrospective case control study from Australia found a 1 in 4000 risk of BWS in their in-vitro population, several times higher than the general population. Another study found that children conceived by in vitro fertilisation (IVF) are three to four times more likely to develop the condition. No specific type of ART has been more closely associated with BWS. The mechanism by which ART produces this effect is still under investigation.
Beckwith–Wiedemann syndrome has an estimated incidence of one in 13,700; about 300 children with BWS are born each year in the United States. The exact incidence of BWS is unknown because of the marked variability in the syndrome's presentation and difficulties with diagnosis. The number of reported infants born with BWS is most likely low because many are born with BWS, but have clinical features that are less prominent and therefore missed. BWS has been documented in a variety of ethnic groups and occurs equally in males and females.
Children conceived through in vitro fertilization have a three to fourfold increased chance of developing Beckwith–Wiedemann syndrome. It is thought that this is due to genes being turned on or off by the IVF procedures.
In the 1960s, Dr. John Bruce Beckwith, an American pathologist and Dr. Hans-Rudolf Wiedemann, a German pediatrician, independently reported cases of a proposed new syndrome. Originally termed EMG syndrome (for exomphalos, macroglossia, and gigantism), this syndrome over time became known as Beckwith–Wiedemann syndrome or Wiedemann Beckwith syndrome.
Originally, Dr. Hans-Rudolf Wiedemann (born 16 February 1915, Bremen, Germany, died 4 August 2006, Kiel) coined the term exomphalos-macroglossia-gigantism (EMG) syndrome to describe the combination of congenital abdominal wall defects as hernia (exomphalos), large tongues (macroglossia), and large bodies and/or long limbs (gigantism). Over time, this constellation was renamed Beckwith–Wiedemann syndrome following the autoptical observations of Prof. John Bruce Beckwith (born 18 September 1933, Spokane, Washington), who also observed a severe increase in the size of the adrenal glands in some of these patients.
- ↑ "Clinical and molecular features of children with Beckwith–Wiedemann syndrome in China: a single-center retrospective cohort study.". Ital J Pediatr 46 (1): 55. 2020. doi:10.1186/s13052-020-0819-3. PMID 32349794. PMC 7191772. https://ijponline.biomedcentral.com/articles/10.1186/s13052-020-0819-3.
- "This article is licensed under a Creative Commons Attribution 4.0 International License". Annotated by Mikael Häggström, MD
- ↑ Shuman, Cheryl; Beckwith, J. Bruce; Weksberg, Rosanna (1993), Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A. et al., eds., "Beckwith–Wiedemann Syndrome", GeneReviews® (University of Washington, Seattle), PMID 20301568, https://www.ncbi.nlm.nih.gov/books/NBK1394/, retrieved 2018-11-30
- ↑ Ranzini, A; Daysalvatore, D; Turner, T; Smulian, J; Vintzileos, A (1997). "Intrauterine growth and ultrasound findings in fetuses with Beckwith–Wiedemann syndrome". Obstetrics & Gynecology 89 (4): 538–542. doi:10.1016/S0029-7844(97)00044-6. ISSN 0029-7844. PMID 9083309.
- ↑ "A novel cyclin encoded by a bcl1-linked candidate oncogene". Nature 350 (6318): 512–5. April 1991. doi:10.1038/350512a0. PMID 1826542. Bibcode: 1991Natur.350..512M.
- ↑ 5.0 5.1 5.2 5.3 "Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith–Wiedemann syndrome with cancer and birth defects". American Journal of Human Genetics 70 (3): 604–11. March 2002. doi:10.1086/338934. PMID 11813134.
- ↑ "Clinical features and natural history of Beckwith–Wiedemann syndrome: presentation of 74 new cases". Clinical Genetics 46 (2): 168–74. August 1994. doi:10.1111/j.1399-0004.1994.tb04219.x. PMID 7820926.
- ↑ 7.0 7.1 "Risk of cancer during the first four years of life in children from The Beckwith–Wiedemann Syndrome Registry". The Journal of Pediatrics 132 (3 Pt 1): 398–400. March 1998. doi:10.1016/S0022-3476(98)70008-3. PMID 9544889. https://zenodo.org/record/1259649.
- ↑ 8.0 8.1 "Overgrowth Syndromes". Journal of Pediatric Genetics 4 (3): 136–43. 2015. doi:10.1055/s-0035-1564440. PMID 27617124.
- ↑ 9.0 9.1 "Congenital mesoblastic nephroma 50 years after its recognition: A narrative review". Pediatric Blood & Cancer 64 (7): e26437. 2017. doi:10.1002/pbc.26437. PMID 28124468. https://discovery.ucl.ac.uk/id/eprint/10070923/1/Pritchard-Jones%20AAM%20pbc-16-1071.pdf.
- ↑ 10.0 10.1 "Screening for Wilms tumor in children with Beckwith–Wiedemann syndrome or idiopathic hemihypertrophy". Medical and Pediatric Oncology 32 (3): 196–200. March 1999. doi:10.1002/(SICI)1096-911X(199903)32:3<196::AID-MPO6>3.0.CO;2-9. PMID 10064187.
- ↑ "Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith–Wiedemann syndrome or isolated hemihyperplasia". The Journal of Pediatrics 143 (2): 270–2. August 2003. doi:10.1067/S0022-3476(03)00306-8. PMID 12970646.
- ↑ Online Mendelian Inheritance in Man (OMIM) 130650
- ↑ Pappas, J. (April 2015). "The Clinical Course of an Overgrowth Syndrome, From Diagnosis in Infancy Through Adulthood: The Case of Beckwith-Weidemann Syndrome". Current Problems in Pediatric and Adolescent Health Care 45 (4): 112–117. doi:10.1016/j.cppeds.2015.03.001. PMID 25861997.
- ↑ "Hypoglycemia in Beckwith–Wiedemann syndrome". Seminars in Perinatology 24 (2): 164–71. April 2000. doi:10.1053/sp.2000.6366. PMID 10805171.
- ↑ Great Ormond Street Hospital, Great Ormond Street Hospital. "Beckwith–Wiedemann syndrome (BWS)". Great Ormond Street Hospital. https://www.gosh.nhs.uk/conditions-and-treatments/conditions-we-treat/beckwith-wiedemann-syndrome-bws/.
- ↑ "Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review". American Journal of Medical Genetics 79 (4): 274–8. October 1998. doi:10.1002/(SICI)1096-8628(19981002)79:4<274::AID-AJMG8>3.0.CO;2-M. PMID 9781907.
- ↑ "Factors associated with preterm delivery in mothers of children with Beckwith–Wiedemann syndrome: a case cohort study from the BWS registry". American Journal of Medical Genetics Part A 134A (2): 187–91. April 2005. doi:10.1002/ajmg.a.30595. PMID 15723285.
- ↑ "Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature". Human Genetics 74 (2): 143–54. October 1986. doi:10.1007/BF00282078. PMID 3770742.
- ↑ "In vitro fertilization may increase the risk of Beckwith–Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene". American Journal of Human Genetics 72 (5): 1338–41. May 2003. doi:10.1086/374824. PMID 12772698.
- ↑ "Beckwith–Wiedemann syndrome and assisted reproduction technology (ART)". Journal of Medical Genetics 40 (1): 62–4. January 2003. doi:10.1136/jmg.40.1.62. PMID 12525545.
- ↑ 21.0 21.1 "Association between Beckwith–Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients". Fertility and Sterility 83 (2): 349–54. February 2005. doi:10.1016/j.fertnstert.2004.07.964. PMID 15705373.
- ↑ "Beckwith–Wiedemann syndrome and IVF: a case-control study". American Journal of Human Genetics 75 (3): 526–8. September 2004. doi:10.1086/423902. PMID 15284956.
- ↑ "Rare congenital disorders, imprinted genes, and assisted reproductive technology". Lancet 361 (9373): 1975–7. 2003. doi:10.1016/S0140-6736(03)13592-1. PMID 12801753.
- ↑ "Exomphalos-macroglossia-gigantism syndrome in Jamaican infants". American Journal of Diseases of Children 119 (4): 316–21. April 1970. doi:10.1001/archpedi.1970.02100050318006. PMID 5434588.
- ↑ BBC, Horizon (2005). "BBC - Science & Nature - Horizon". https://www.bbc.co.uk/sn/tvradio/programmes/horizon/ghostgenes.shtml. "Beckwith–Wiedemann Syndrome – a rare disorder linked to abnormal gene expression. It has been shown that babies conceived by IVF have a three- to four-fold increased chance of developing this condition."
- ↑ "BBC - Horizon - 2005 - The Ghost In Your Genes". BBC Horizon. BBC. 2005. https://www.dailymotion.com/video/x7pfn88. "See from time offset 16:40 in the video"
- ↑ Ghost in Your Genes on Vimeo
- ↑ Beckwith, J. Bruce (1963). "Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig cell hyperplasia - another syndrome?". Los Angeles.
- ↑ Wiedemann HR (September 1964). "Familial malformation complex with umbilical hernia and macroglossia - a "new syndrome"?" (in fr). Journal de Génétique Humaine 13: 223–32. PMID 14231762.
- ↑ Biographical note
Original source: https://en.wikipedia.org/wiki/Beckwith–Wiedemann syndrome. Read more